Clinical trials in Dijon – page 24

819 clinical trials in Dijon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Dijon at a glance

819

clinical trials

Research sites2

Quick filters

819 trials in Dijon

Open in trial search

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug

France

Participants:18–64 years · 65+ years
Substances:MK-1084
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Adenocarcinoma gastric+4

Recruiting

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiac failure

Recruiting

Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

Registered drugNo placebo

Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Hydrochlorothiazide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Balcinrenone
Sponsor:AstraZeneca AB

Contact Research Centre

Thyroid cancer+2

Recruiting

Study Comparing Two Treatment Strategies for Intermediate-Risk Thyroid Cancer Using Sodium Iodide (131I) in Patients with Post-Surgery Evaluation

Registered drugNo placebo

Study Comparing Two Treatment Strategies for Intermediate-Risk Thyroid Cancer Using Sodium Iodide (131I) in Patients with Post-Surgery Evaluation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sodium iodide (131I)
Sponsor:Centre Francois Baclesse

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Ovarian cancer

Recruiting

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Arcagy Gineco

Contact Research Centre

Soft tissue sarcoma

Recruiting

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

Registered drugNo placebo

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dacarbazine Citrate
Sponsor:Oncopole Claudius Regaud

Contact Research Centre

Macular degeneration

Recruiting

Study of dimethyl fumarate to slow the progression of geographic atrophy in patients with age-related macular degeneration (dry form)

Registered drugNo placebo

Study of dimethyl fumarate to slow the progression of geographic atrophy in patients with age-related macular degeneration (dry form)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dimethyl Fumarate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Dijon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for head and neck cancer, gastric cancer, and multiple types of lung cancer. Research encompasses novel therapeutic approaches and targeted treatments.

Head & Neck Squamous Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer

Several studies are evaluating new combination therapies and immunotherapy approaches for better treatment outcomes.

02 Immunology & Infectious Diseases

Research focusing on immune system responses and vaccine development, with particular emphasis on COVID-19 prevention and treatment strategies. Studies include innovative approaches to boosting immunity.

COVID-19 Vaccine Development
Immune System Enhancement
Preventive Medicine

Trials are investigating both intranasal and traditional vaccination methods for optimal immune response.

03 Cardiovascular Medicine

Studies focusing on heart disease management and prevention, including innovative treatments for acute myocardial infarction and heart failure prevention strategies.

Acute Myocardial Infarction
Heart Failure Prevention
Pain Management in Cardiac Conditions

Research includes novel pain management approaches and preventive treatments for cardiac conditions.

Back to France All countries